home · filing · 0001104659-26-067474
8-K filed May 28, 2026, 4:05 PM ET
ticker BCLI
CIK 0001137883
leadership
confidence high
sentiment positive
materiality 0.65
BrainStorm appoints former FDA official Peter Pitts to Board ahead of ALS trial
BRAINSTORM CELL THERAPEUTICS INC.
Appointed Peter Pitts, former FDA Associate Commissioner, to the Board effective May 25, 2026.
Pitts granted option for 150,000 shares; half vested immediately, half vest in six months.
Company preparing to initiate Phase 3b ENDURANCE trial for NurOwn in ALS under FDA Special Protocol Assessment.
Board expanded from seven to eight directors; Pitts determined independent under SEC rules.
Executive movements
Machine-extracted from this filing. Every card cites the SEC source. See all recent executive movements .
Effective 2026-05-25
Filed May 28, 2026, 4:05 PM ET
appointed Peter Pitts to serve as a director of the Company, effective as of the same day
Key facts
Extracted from this filing and checked against the source text.
Executive change
SEC 8-K Item 5.02
confidence 0.95
Peter Pitts was appointed as Director at BRAINSTORM CELL THERAPEUTICS INC..
Action appointed
Role Director
Exact text from the filing
appointed Peter Pitts to serve as a director of the Company, effective as of the same day
View on SEC.gov
Source: SEC EDGAR
accession 0001104659-26-067474
This headline and bullets were generated automatically by deepseek-v4-flash:cloud@v2 from the public filing. Read the source on SEC.gov before relying on any specific claim. Not investment advice.
See methodology for how this pipeline works.